A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

NCT02091752 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to low enrollment.

Conditions

Primary Myelofibrosis

Interventions

DRUG: Ruxolitinib

Sponsor

Novartis Pharmaceuticals